Exhibit 10.6

[***] PORTIONS OF THIS EXHIBIT HAVE BEEN REDACTED PURSUANT TO ITEM 601(B)(2) OF REGULATIONS S-K AS (I) NOT MATERIAL AND (II) LIKELY TO CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. THE COMPANY HEREBY UNDERTAKES TO FURNISH UNREDACTED COPIES OF THIS EXHIBIT UPON REQUEST BY THE SECURITIES AND EXCHANGE COMMISSION; PROVIDED, HOWEVER, THAT THE COMPANY MAY REQUEST CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 OF THE EXCHANGE ACT FOR SUCH UNREDACTED COPIES OF THIS EXHIBIT. 

SYNERGIQC NETWORK AND RESEARCH FUNDING AGREEMENT

THIS AGREEMENT (the “Agreement”) is made and entered into:

PREAMBLE

WHEREAS CQDM is a not-for-profit organization created to promote, stimulate and support drug research, development and discovery and, accordingly, to fund and manage the fulfilment of innovative research projects aimed at developing tools, enabling technologies, or new drug candidates that facilitate and accelerate the drug discovery and development process;

WHEREAS Inspirevax is a company pursuing the development of mucosal adjuvants for use in vaccines and immunotherapies administered by the intranasal route;

WHEREAS Oragenics is a development-stage company dedicated to fighting infectious diseases, including those caused by coronaviruses and multidrug-resistant organisms;

WHEREAS NRC is a public institution and accordingly its services to be rendered hereunder are exonerated from applicable taxes;

WHEREAS the Project Summary attached hereto, the Contract Documentation identified therein and the intervention(s) of the Investigator(s) attached hereto form an integral part of this Agreement and all capitalized terms used herein are defined in the Project Summary and Contract Documentation;

WHEREAS in case of earlier start of the Project, the Research Entity(ies) and Co-Funder(s) acknowledge that they have been informed in due time and understood that this Agreement would apply and govern retroactively as if signed on such earlier start date indicated in the Project Summary, as applicable, unless indicated otherwise in this Agreement;

WHEREAS the Co-Funder(s) and the Third-Party Funder(s) (if any) selected the Project for funding, and the Research Entity(ies) agree(s) to perform the Project in accordance with this Agreement;

NOW THEREFORE, in consideration of the foregoing premises, the Parties have caused their duly authorized representatives to sign this Agreement as of May 29 2023:

INTERVENTIONS

The undersigned, being a Principal Investigator or Co-Investigator, having read and understood this Agreement, hereby agrees to be bound by the obligations of the Principal Investigator or Co- Investigator, whichever applies, to act in accordance with all the terms and conditions of this Agreement.

In addition, by accepting funding from the Granting Agency(ies) through CQDM, the undersigned understand that maintaining public trust in the integrity of researchers is fundamental to building a knowledge-based society and they affirm that they have read and they agree to conduct the Project in accordance with (i) internal ethical principles in force in concerned Research Entity, the principles established in the Tri-Council Policy Statement (available at: https://ethics.gc.ca/eng/tcps2-eptc2_2018_chapter3-chapitre3.html) and other applicable scientific, ethical and professional standards regulation, guidance and laws namely as it relates to ethical review, consent process, confidentiality and privacy; (ii) Granting Agency(ies) Policies and Guidelines (available at: https://science.gc.ca/eic/site/063.nsf/eng/h_1E7A5F18.html); (iii) the Agreement and, when applicable, (iv) terms and conditions set forth by the Third-Party Funder(s).

Principal Investigator

The NRC Principal Investigator’s participation, work and compliance with the Project governed by the NRFA Agreement is committed and confirmed by the signature of the person authorized to sign on behalf of NRC on the signature page.

Name: Yves Durocher

Date: NA

Co-Investigator(s)

The NRC Co-Investigator’s participation, work and compliance with the Project governed by the NRFA Agreement is committed and confirmed by the signature of the person authorized to sign on behalf of NRC on the signature page.

Name: Matthew Stuible

Date: NA

(End of signatures)

SCHEDULE 1

PROJECT EXECUTIVE SUMMARY

Challenge: As the global SARS-CoV-2 situation continues to evolve, the strategy of focusing vaccine development on the currently dominant variant of concern should be complemented by approaches that provide more durable and wider protection against future emerging variants that can be quickly manufactured for urgent deployment.

Solution: We believe that a spike antigen or mixture of antigens, possibly based in part on zoonotic virus sequences, could be designed as a booster for individuals already immunized with current SARS-CoV-2 vaccines to provide better protection against emerging variants with yet unknown spike sequences. Leveraging the NRC expertise in production, characterization and pre-clinical evaluation of recombinant spike proteins as candidate subunit vaccine antigens, the proposed project will support development of an intranasal COVID-19 vaccine that induces an optimal pan-variant antibody response. A diverse set of recombinant zoonotic spike proteins, chimeric and stabilized constructs that will be designed de novo based on well-established protein engineering approaches will be screened initially. These proteins will be used as booster doses in mice primed with 2 doses of a reference-strain SARS-CoV-2 spike-based vaccine and mice sera will be profiled for antibody specificity against a range of SARS-CoV-2 variants. In subsequent stages of the project, iterative protein engineering, CHO cell line development and in vivo experiments will be performed to narrow down the number of candidates and refine dosing and antigen combination strategies. A research cell bank (RCB) readily amenable to Master Cell Bank (MCB) generation that eventually would be used for clinical trials will also be created to ensure a rapid manufacturing in response to the emergence of new SARS-CoV-2 variants.

Expected Achievements/Impact: Ultimately, the project will deliver two to four well- characterized stable CHO pools (RCBs) expressing vaccine antigens with well-established preclinical efficacy (using intranasal immunization). These 2-4 novel antigens will be rapidly deployable to generate MCBs and Drug Substance (DS) using a de-risked, scaled manufacturing platform (developed already for the reference strain spike antigens) for clinical trials, enabling an efficient, informed response to future variants of concern. A corresponding set of analytical methods to characterize these antigens will be created in parallel as part of this proposal to facilitate the rapid scale up.

SCHEDULE 2(A)

MILESTONES & DELIVERABLES

MILESTONES

[***]

DELIVERABLES

[***]

SCHEDULE 2(B)

GANTT CHART

[***]

SCHEDULE 2(C)

FUNDING STRUCTURE

[***]

SCHEDULE 2(D)

BUDGET

[***]

SCHEDULE 2(E)

PAYMENT SCHEDULE

[***]

SCHEDULE 3

GENERAL TERMS & CONDITIONS

[See attached document]

SYNERGIQC GENERAL TERMS & CONDITIONS

In the Agreement, the following terms shall have the following meaning:

“Administrative Fee” means the non reimbursable fee set forth in the Funding Structure payable to CQDM upon execution of the Agreement or as otherwise agreed to in the Payment Schedule in consideration of the enabling support offered by CQDM hereunder, in accordance with the requirements of the Granting Agency(ies);

“Agreement” means the Network and Research Funding Agreement, the Project Summary, the Contract Documentation identified therein and the intervention(s) of the Investigator(s);

“Budget” means the corresponding schedule included in the Contract Documentation;

“Co-Investigator(s)” means the person(s) identified as such in the Project Summary or the person(s) intervening as such to the Agreement, who shall manage the research team members within each Research Entity under the coordination of the Principal Investigator;

“Completion Date” means the completion date set forth in the Project Summary which shall not exceed thirty-six (36) months;

“Confidential Information” means all confidential information disclosed by a Party (referred to in this capacity as the “Provider”) to another Party (referred to in this capacity as the “Recipient”) including, without limitation, the terms and conditions of the Agreement and any confidential and/or proprietary information and documents relating to (i) the Project, including without limitation, all data, trade secrets, know-how and other proprietary information relating thereto and their related conception, development, use, modification and manufacturing, (ii) the Provider’s business, finances, operations, research and development activities, products or services; and (iii) all other information which is not generally known to the public or is by its nature or the circumstances in which it is made available to the Recipient, is such that it would generally be considered confidential or proprietary. Without limiting the generality of the foregoing, Confidential Information includes, without limitation, all forms of Confidential Information and support containing Confidential Information, whether oral, written or digital, whether provided, disclosed, furnished or prepared before, on or after the Effective Date of the Agreement, including all analyses, compilations, data, studies, notes, reports or other documents prepared by or for the Provider, based upon or including any of such Confidential Information and, in all cases, shall include all copies and tangible or intangible embodiments thereof, in whatever form or medium. However, Confidential Information shall not include the information that (i) is already known to the Recipient; (ii) after disclosure, became part of the public domain otherwise than through the fault of the Recipient; (iii) was in the possession of the Recipient at the time of disclosure and was not acquired, directly or indirectly, from the Provider under an obligation of confidentiality; or (iv) was received by the Recipient on a non-confidential basis from a third party, provided that such third party is not known by the Recipient to be bound by a confidentiality agreement with or other obligation of secrecy to the Provider.

“Contract Documentation” means the Project Proposal submitted to CQDM and the documents identified as such in the Project Summary which are hereby incorporated by reference in the Agreement;

“Co-Funder(s)” means the Party(ies) entering as such into the Agreement (if any);

“CQDM Funds” means the CQDM Funds set forth in the Funding Structure to be disbursed by CQDM to co-fund Eligible Expenses of the Project in accordance with the Agreement, which includes funds received from the Granting Agency(ies);

“Deliverables” means the deliverables of the Project described in the corresponding schedule included in the Contract Documentation;

“Effective Date” means the earlier of (i) the execution date of the Agreement specified at the beginning of the signature block; or (ii) the anticipated project start date specified in the Project Summary, if any, and upon which the Agreement becomes effective.;

SYNERGIQC GENERAL TERMS & CONDITIONS

“Eligible Expenses” means the expenses described in the Budget and made by the Research Entity(ies) in compliance with eligible expenses and travelling rules and other Granting Agency(ies) Policies and Guidelines as updated and supplemented by the Granting Agency(ies) from time to time;

“Funders” means collectively CQDM and the Co-Funder(s) (if any) and “Funder” means any of them;

“Funding Structure” means the corresponding schedule included in the Contract Documentation describing the CQDM Funds, the Matching Funds and the Administrative and annual membership fees, as applicable;

“Funds” means, collectively, the CQDM Funds and the Matching Funds;

“Funds Manager” means the sole Research Entity, when only one Research Entity enters into the Agreement, or the Research Entity identified as such in the Project Summary when multiple Research Entities enter into the Agreement, as applicable;

“General terms & conditions” means these general terms & conditions;

“Granting Agency(ies)” means governments and governments agencies which have financially contributed to the CQDM Funds, which includes the Ministère de l’Économie, de l’Innovation et de l’Énergie of the Government of Québec (“MEIE”);

“Granting Agency(ies) Policies and Guidelines” means rules established by the Granting Agency(ies) as updated from time to time;

“IP Management and Commercialization Agreement” means the agreement referred to in section 8 of these General terms & conditions and attached under corresponding schedule included in the Contract Documentation;

“Investigator(s)” means collectively the Principal Investigator(s) and the Co-Investigator(s) (if any) and “Investigator” means any of them;

“Lead Research Entity” means the Research Entity identified as such in the Project Summary when multiple Research Entities enter into the Agreement or the sole Research Entity when only one Research Entity enters into the Agreement, as applicable;

“Liability” or “Liabilities” means any losses, damages, fines, costs, liabilities and expenses (including the reasonable fees, costs and expenses of attorneys and expert and court costs), to be paid further to a court order or settlement based on a claim for any civil, criminal, statutory or regulatory liability;

“Matching Funds” means the funds set forth in the Funding Structure and payable by the Co- Funder(s) (if any) and the Third-Party Funder(s) (if any) to co-fund the Project with CQDM as detailed in the Payment Schedule;

“Milestones” means the milestones described in the corresponding schedule included in the Contract Documentation;

“Parties” means collectively CQDM, the Co-Funder(s) (if any) and the Research Entity(ies) and “Party” means any of them;

“Payment Schedule” means the corresponding schedule included in the Contract Documentation;

“Principal Investigator(s)” means the person(s) identified as such in the Project Summary or the person(s) intervening as such to the Agreement, who shall manage the Project in accordancewith the Agreement;

“Project” means the research project presented in the Project Proposal and as identified, amended and supplemented by the Agreement, including, for clarity, the Funding Structure, the Milestones, the Deliverables, the Gantt Chart, the Budget and the Payment Schedule;

SYNERGIQC GENERAL TERMS & CONDITIONS

“Project Proposal” means the proposal and supplement and amendments thereto, if any, provided to CQDM to apply for funding of the Project;

“Project Summary” means the corresponding schedule included in the Contract Documentation;

“Reports” means the reports listed in the Project Summary to be completed by the Research Entity(ies) in forms provided by CQDM or as otherwise indicated by CQDM from time to time;

“Research Entity(ies)” means the Party(ies) entering as such into the Agreement; “Term” has the meaning set out in section 12 of these General terms & conditions;

“Third-Party Fund(s)” means (if any) the portion of the Matching Funds set forth in the Funding Structure payable by Third-Party Funder(s) as detailed in the Payment Schedule; and

“Third-Party Funder(s)” means (if any) the entity(ies) identified as such in the Funding Structure and that is/are not a party to the Agreement.

In consideration of performing a Project co-funded by CQDM, and provided that the Research Entity(ies) and the Co-Funder(s) are not in default hereunder, each Research Entity and Co- Funder(s) shall be or become, as soon as practically possible following the Effective Date, a member of CQDM of a class of membership to be determined by CQDM, pay the annual membership fees as determined by CQDM and become part of the network created by CQDM’s activities.

The Research Entity(ies) and the Investigator(s) undertake to:

SYNERGIQC GENERAL TERMS & CONDITIONS

SYNERGIQC GENERAL TERMS & CONDITIONS

The Research Entity(ies) will provide Reports to CQDM at the frequency and within timelines set forth in the Project Summary and other information reasonably required by CQDM and the Co- Funder(s) (if any) from time to time. CQDM is hereby expressly authorized to share these Reports and other information with the Co-Funder(s) and Third-Party Funder(s) (if any) and the Granting Agency(ies).

SYNERGIQC GENERAL TERMS & CONDITIONS

SYNERGIQC GENERAL TERMS & CONDITIONS

SYNERGIQC GENERAL TERMS & CONDITIONS

CQDM may terminate the Agreement in whole or as to the concerned Party, with immediate effect upon written notice to the other Party(ies), if:

SYNERGIQC GENERAL TERMS & CONDITIONS

Except as specifically set out in the Agreement, neither the Research Entity(ies) nor the Investigator(s) makes any representation or warranty regarding the results of the Project and disclaim any warranty, express, legal or implied of merchantability or fitness for a particular purpose.

If to CQDM:

E-mail: contracts@cqdm.org

Attention: the CQDM President

or to such other e-mail address designated in writing by a Party to the other Party. Notices delivered by e-mail (with confirmation of delivery) shall be deemed received on the date sent, provided that such transmittal occurs prior to 5:00 P.M. Eastern Standard Time, and if sent thereafter, any e-mail shall be deemed received on the next following [business] day.

Failing the ability to send an e-mail Notice pursuant to this Section due to the receipt of an automated non delivery message from an e-mail system (a “bouncing email”), then such Notice shall be either hand delivered or mailed by overnight courier postage prepaid and addressed as follows:

If to CQDM:

630 René-Lévesque Blvd. West, 20th floor, Montreal (Quebec) H3B 1S6

Attention of: the CQDM President

SYNERGIQC GENERAL TERMS & CONDITIONS

[The remainder of this page is intentionally left blank.]

SCHEDULE 4

RULES ESTABLISHED BY THE GOVERNMENT OF QUÉBEC CONCERNING ELIGIBLE EXPENSES INCLUDING RELATED TRAVEL

Dépenses admissibles à la SUBVENTION

Les dépenses énumérées dans cette annexe sont admissibles aux fins du calcul de la SUBVENTION en vertu de la présente convention. Ces dépenses admissibles sont composées des coûts liés directement aux projets de recherche, de valorisation, de transfert et d’innovation du BÉNÉFICIAIRE.

Coûts directs des projets

Les coûts directs des projets font référence aux dépenses directement imputables aux projets financés ou réalisés par le BÉNÉFICIAIRE. Ils englobent notamment la rémunération du personnel de recherche, les bourses à des étudiants et d’autres frais directement imputables aux projets.

Coûts indirects des projets

Les coûts indirects des projets font référence à des dépenses de fonctionnement additionnelles découlant des projets de recherche, mais ne pouvant pas être spécifiquement imputées à ceux-ci.

Ils comprennent les frais liés à l’exploitation et à l’entretien des infrastructures, à la gestion et à l’administration des projets, ainsi qu’au respect des différents règlements et normes en vigueur.

Spécificités:

Dépenses admissibles et barème des frais de déplacement

Les frais de déplacement réfèrent aux frais encourus alors qu’une personne se déplace à l’extérieur de son territoire habituel de travail.

La présente annexe présente un résumé du recueil des politiques de gestion en vigueur au gouvernement du Québec concernant les directives relativement aux frais de déplacement qui doivent être suivies par le BÉNÉFICIAIRE et qui sont indiquées sur le site Web se trouvant au lien suivant: https://www.tresor.gouv.qc.ca/fileadmin/PDF/secretariat/Directive_frais_remboursables.pdf

a) Frais de déplacement au Québec

Les frais de déplacement réfèrent aux frais encourus alors qu’une personne se déplace à l’extérieur de son territoire habituel de travail.

La présente annexe concerne les frais de déplacement liés à certains modes de transport, à l’hébergement en établissement hôtelier, ainsi qu’aux frais de restaurant.

Transport

Le recours au transport en commun doit être favorisé dans la mesure où cela est plus économique que l’usage d’un véhicule personnel.

Lors de l’utilisation d’un véhicule personnel, les taux suivants sont admissibles selon le kilométrage applicable au cours de l’exercice financier du BÉNÉFICIAIRE:

Si un moyen approprié de transport en commun est disponible et qu’un véhicule personnel est utilisé, le taux admissible est réduit à 0,170 $   par kilomètre ainsi parcouru.

Hébergement en établissement hôtelier

Les indemnités quotidiennes maximales sont les suivantes pour l’hébergement dans un établissement hôtelier:

Frais de repas

Les indemnités quotidiennes maximales sont les suivantes:

Les taux ci-dessus incluent les taxes et les pourboires.

b) Frais de déplacement hors du Québec

La présente section concerne les frais encourus hors du Québec pour les programmes dans lesquels ce type de frais s’applique.

Un barème tenant compte des variations de taux de change est édité par le Conseil du trésor et disponible sur demande auprès du ministère de l’Économie et de l’Innovation (MEI).

Transport

Le recours au transport en commun doit être favorisé dans la mesure où cela est plus économique que l’usage d’un véhicule personnel.

La copie du billet de train, d’avion ou de location de véhicule est exigée à titre de pièce justificative, ainsi que la copie de la facture d’achat.

Pour les billets de transport urbain, le justificatif d’achat est exigé pour la demande de remboursement de plus d’un trajet (exemple : billet forfaitaire à la journée/sur plusieurs jours ou billet par 10 unités).

En cas d’utilisation d’un véhicule personnel pour un déplacement au Canada ou aux États-Unis, un calcul basé sur le coût moyen du litre d’essence au Québec et aux États-Unis s’applique. Les résultats du calcul des indemnités de kilométrage allouées lors de déplacements à l’extérieur du Canada seront fournis sur demande.

Hébergement et repas en établissement hôtelier

Le barème appliqué est celui utilisé par les délégations du Québec à l’étranger; il peut être obtenu auprès du MEI.

Les montants maximaux portés au barème n’incluent pas les taxes en vigueur dans les pays concernés qui, lorsqu’elles sont appliquées, doivent être remboursées en sus.

À titre de pièce justificative, la facture et la preuve de paiement sont exigées.

Taux de change

Tout écart de tarification découlant des variations des taux de change entre les frais de repas et d’hébergement encourus et la tarification prévue par le Conseil du trésor peut être remboursable sur présentation de pièces justificatives témoignant du taux de conversion de la monnaie canadienne en monnaie locale.

SCHEDULE 5

IP MANAGEMENT AND COMMERCIALIZATION AGREEMENT

[See attached document]

	National Research Council Canada	Conseil national de recherches Canada	Collaborative Research Agreement
	Non-Exclusive Licence Included ☐
	Business Confidential-Protected B

(Individually referred to as a “Party” and collectively referred to as the “Parties”; Collaborator-1 and

Collaborator-2 individually referred to as “Collaborator” and collectively referred to as

“Collaborators”)

WHEREAS

IN CONSIDERATION of the mutual covenants hereunder, the Parties agree as follows:

	National Research Council Canada	Conseil national de recherches Canada	Collaborative Research Agreement
	Non-Exclusive Licence Included ☐
	Business Confidential-Protected B

SIGNED by the Collaborator-1 at Tampa, Florida, U.S.A.

	National Research Council Canada	Conseil national de recherches Canada	Collaborative Research Agreement
	Non-Exclusive Licence Included ☐
	Business Confidential-Protected B

ANNEX IP: INTELLECTUAL PROPERTY

	National Research Council Canada	Conseil national de recherches Canada	Collaborative Research Agreement
	Non-Exclusive Licence Included ☐
	Business Confidential-Protected B